Equillium Cleared in Australia for EQ504 Phase 1 Study

Equillium has received clearance in Australia to initiate a randomized, double-blind, placebo-controlled Phase 1 study of EQ504 in healthy subjects. Dosing is expected by early November 2026, with topline proof-of-mechanism data anticipated approximately six months after the study begins.